Regardless of chemotherapy backbone, and adjusting for patient and tumor characteristics, the only instance in which we observed a clear survival advantage was with receipt of EGFR inhibitors (compared with neither EGFR inhibitors nor VEGF inhibitors) in patients with RAS-WT tumors (adjusted hazard ratio [aHR], 0.85; 95% CI, 0.74-0.98). The gene discussed is VEGFA; the disease is neoplasm.